Dimension Therapeutics Inc (NASDAQ:DMTX) has earned an average rating of “Hold” from the seven brokerages that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $4.60.
Separately, Chardan Capital reaffirmed a “buy” rating on shares of Dimension Therapeutics in a research note on Friday, December 22nd.
Shares of Dimension Therapeutics (DMTX) opened at $5.95 on Tuesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.33 and a current ratio of 2.01. Dimension Therapeutics has a 12 month low of $1.05 and a 12 month high of $6.10. The firm has a market cap of $149.06 and a P/E ratio of -2.67.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/13/dimension-therapeutics-inc-dmtx-given-average-rating-of-hold-by-brokerages.html.
About Dimension Therapeutics
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.